Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 6 Comparison of training set and validation set features, n (%)

Characteristic	Test (n = 38)	Train (n = 88)	χ2	P value
HBV DNA (IU/mL)			3.06	0.080
HBV > 2000	13 (34.21)	45 (51.14)
HBV ≤ 2000	25 (65.79)	43 (48.86)
HBe			0.38	0.537
Negative	28 (73.68)	60 (68.18)
Positive	10 (26.32)	28 (31.82)
Child-Pugh class			0.27	0.603
A	21 (55.26)	53 (60.23)
B	17 (44.74)	35 (39.77)
PVTT			2.62	0.106
No	27 (71.05)	49 (55.68)
Yes	11 (28.95)	39 (44.32)
BCLC stage			0.00	1.000
B	19 (50.00)	44 (50.00)
C	19 (50.00)	44 (50.00)
Metastasis			0.50	0.480
No	19 (50.00)	50 (56.82)
Yes	19 (50.00)	38 (43.18)
AFP (ng/mL)			0.03	0.872
> 1210	17 (44.74)	38 (43.18)
≤ 1210	21 (55.26)	50 (56.82)
Sex			1.34	0.247
Female	11 (28.95)	35 (39.77)
Male	27 (71.05)	53 (60.23)
BMI			0.02	0.880
≤ 25	15 (39.47)	36 (40.91)
> 25	23 (60.53)	52 (59.09)
Age (years)			1.78	0.182
< 60	18 (47.37)	53 (60.23)
≥ 60	20 (52.63)	35 (39.77)
ECOG			0.54	0.464
0-1	22 (57.89)	57 (64.77)
2	16 (42.11)	31 (35.23)
ALT (U/L)			0.22	0.642
> 40	16 (42.11)	41 (46.59)
≤ 40	22 (57.89)	47 (53.41)
Total bilirubin (μmol/L)			2.81	0.094
> 34	28 (73.68)	51 (57.95)
≤ 34	10 (26.32)	37 (42.05)
Diabetes			3.24	0.072
No	25 (65.79)	71 (80.68)
Yes	13 (34.21)	17 (19.32)
Hypertensive			1.12	0.289
No	13 (34.21)	22 (25.00)
Yes	25 (65.79)	66 (75.00)
Cirrhosis			0.01	0.911
No	22 (57.89)	50 (56.82)
Yes	16 (42.11)	38 (43.18)
Smoking			1.21	0.272
No	28 (73.68)	56 (63.64)
Yes	10 (26.32)	32 (36.36)
Alcohol			0.27	0.605
No	26 (68.42)	56 (63.64)
Yes	12 (31.58)	32 (36.36)
Interventional			0.94	0.332
No	23 (60.53)	45 (51.14)
Yes	15 (39.47)	43 (48.86)

HBV: Hepatitis B virus; PVTT: Portal vein tumor thrombosis; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; ALT: Alanine aminotransferase.